Suven Pharmaceuticals Q2 FY25 revenue grows 12% in Q2
Pharma CDMO business has posted a 40% YoY in Q2 driven by BD efforts and backed by macro tailwinds
Pharma CDMO business has posted a 40% YoY in Q2 driven by BD efforts and backed by macro tailwinds
In Q2 FY25, our crop protection segment reported revenue of Rs. 159 crore, with an EBIT margin of 5%
The program aims to accelerate the development of 6 Indian innovations to improve ease of access to diagnostics and treatment monitoring
Hospital business revenues increase 13.9% to Rs. 1,655 crore
Medanta is expected to incur a project capex of ~Rs. 600 crores in next 3-4 years
The group plans to establish new hospitals in Kerala developing large health cities in Kochi and Kozhikode
The recognition from Malaysia's NPRA, a member of PIC/S, opens doors to new global business opportunities
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
The company reported a net profit of Rs 46.15 crore in Q2 FY25 as compared to Rs 23.88 crore in Q2 FY24
Subscribe To Our Newsletter & Stay Updated